Last reviewed · How we verify
NCT02970747: CARO
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
trial testing Carfilzomib in Multiple Myeloma in Relapse in 359 participants. Completed in 26 April 2025.
26 April 2025
Quick facts
| Lead sponsor | iOMEDICO AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 359 |
| Start date | 25 October 2016 |
| Primary completion | 26 April 2025 |
| Estimated completion | 26 April 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Carfilzomib (carfilzomib) — full drug profile →
Conditions studied
- Multiple Myeloma in Relapse — all drugs for Multiple Myeloma in Relapse →
Sponsor
iOMEDICO AG — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma in Relapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this non-interventional study (NIS) is to evaluate patients' adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in combination with daratumumab and dexamethasone in adult patients with multiple myeloma (MM) who have received at least one prior therapy in a real-life setting.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233 -
Treatment adherence and effectiveness in patients treated with carfilzomib-based therapy combinations for relapsed/refractory multiple myeloma in Germany: interim results from the non-interventional CARO study.
Knauf W, Uhlig J, von der Heyde E, Losem C, et al · · 2025 · PMID 39654362 · DOI 10.1080/10428194.2024.2436034
Verify or expand the search:
- PubMed search for NCT02970747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Carfilzomib
Trials testing the same drug.
- NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf · Phase 1, PHASE2 · not yet recruiting
- NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat · Phase 2 · not yet recruiting
- NCT06918990 — Treatment of Antibody-Mediated Rejection (ABMR) With CarBel · Phase 2 · not yet recruiting
- NCT07082270 — Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma · Phase 1 · withdrawn
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other recruiting trials for Multiple Myeloma in Relapse
Currently open trials in the same condition.
- NCT07096778 — Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT06822972 — HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · Phase 2 · recruiting
- NCT07032129 — Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT07248176 — Universal CAR-T Cell Therapy for MM · NA · recruiting
- NCT06846905 — Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma. · recruiting
Other iOMEDICO AG trials
Trials by the same sponsor.
- NCT06619275 — Ripretinib (QINLOCK®) According to Current SmPC · completed
- NCT06181734 — Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC · completed
- NCT05954780 — Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma · active not recruiting
- NCT05517265 — Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) · active not recruiting
- NCT05284591 — Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02970747 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by iOMEDICO AG
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02970747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing